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Type 2 diabetes mellitus (T2DM) is a non-autoimmune, complex, heterogeneous and polygenic metabolic disease
condition characterized by persistent elevated blood glucose levels (hyperglycemia). India as said to be the diabetic
capital of the world is likely to experience the largest increase in T2DM and a greater number of diabetic
individuals in the world by the year 2030. Identification of specific genetic variations in a particular ethnic group has
a critical role in understanding the risk of developing T2DM in a much efficient way in future. These genetic
variations include numerous types of polymorphisms among which single nucleotide polymorphisms (SNPs) is the
most frequent. SNPs are basically located within the regulatory elements of several gene sequences. There are
scores of genes interacting with various environmental factors affecting various pathways and sometimes even the
whole signalling network that cause diseases like T2DM. This review discusses the biomarkers for early risk
prediction of T2DM. Such predictions could be used in order to understand the pathogenesis of T2DM and to
better diagnostics, treatment, and eventually prevention.
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Overview of type 2 diabetes mellitus
T2DM is a chronic metabolic disorder with a rapidly in-
creasing prevalence highlighting the importance of contin-
ued research and the need for novel methods to both
prevent and treat this pandemic disease. In case of India,
the disease burden is estimated to be 87 million around
2030 [1]. The negative impacts of T2DM are considerable:
as a lifelong disease, which increases morbidity and mor-
tality, ultimately decreasing the quality of life [2]. If dia-
betes is not efficiently controlled, then the patient has a
significantly higher risk of developing complications such
as, hypoglycemia, ketoacidosis, and non-ketotic hyperos-
molar coma. Apart from these, long-standing complica-
tions could be cardiovascular disease, chronic kidney
failure, retinal damage, nerve damage, poor healing of
wounds, gangrene on the feet leading to amputation, and* Correspondence: tasleem24@gmail.com
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reproduction in any medium, provided the orerectile dysfunction etc. The recent global epidemic of
T2DM almost certainly indicates the importance of envir-
onmental triggers such as sedentary lifestyle and dietary
changes over last several decades. Nevertheless T2DM is
amongst those complex diseases for which genetic contri-
bution is well accepted. Identification of genetic compo-
nents of T2DM is the most important area of diabetes
research because elucidation of the diabetes genes (alleles)
will influence all efforts toward a mechanistic understand-
ing of the disease, its complications, cure, treatment and
prevention [3]. Basically, many genes perform key regula-
tory functions in the development of T2DM, which is a
polygenic disorder with multiple genes located on differ-
ent chromosomes contributing to its susceptibility. The
analysis of genetic factors associated with T2DM is further
complicated by the fact that a variety of environmental
factors interact with these genes to produce the disorder.
Thus, identification and characterization of the gene vari-
ants among a particular ethnic group that play a signifi-
cant role in T2DM, is one of the most important areas ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ward a mechanistic understanding of the disease compli-
cations, treatment, cure and prevention.
Candidate genes for type 2 diabetes mellitus
Numerous reports have been published on the genetics of
T2DM with most recent ones showcasing the effect of
SNP’s in various genes corresponding to risk prediction of
T2DM such as, gene variants of Peroxisome Proliferator-
Activated Receptor Gamma (PPAR-γ) [4-6], Angiotensin
Converting Enzyme (ACE) [7-9], Methylene Tetrahydrofo-
late Reductase (MTHFR) [10-14], Fatty Acid Binding
Protein-2 (FABP2) [15-19] and Fat Mass and Obesity asso-
ciated gene (FTO) [20,21]. In this review, we will focus on
candidate genes (PPAR-γ, ACE, MTHFR, FABP2 and
FTO) in which the genetic variants have been well estab-
lished to be functional and shown in more than one study
for their association with T2DM, in various ethnic groups.
Findings from Previously Conducted Meta-Analyses of
different Gene Variant in T2DM are shown in Table 1.
Peroxisome Proliferator-Activated Receptor Gamma
(PPAR-γ) gene
PPARs (isoforms α, δ, and γ) are ligand-activated tran-
scription factors that heterodimerise with retinoid X re-
ceptor (RXR). It has been shown that agonists of PPAR
possess antidiabetogenic, anti-inflammatory, and antioxi-
dant effects. PPAR-γ gene, encoding the nuclear receptor
PPAR-γ, was the first gene reproducibly associated with
T2DM [36]. PPAR-γ gene is located on chromosome 3p25
encodes a nuclear transcription factor involved in the ex-
pression of hundreds of genes. PPAR-γ gene contains 9
exons, spans more than 100 kilobases, because of alterna-
tive mRNA splicing results in the production of 2 protein
isoforms: PPARγ-1 and PPARγ-2 [22]. PPARs constitute a
distinct sub-family of the nuclear receptors that are acti-
vated by naturally occurring fatty acids [40]. The associ-
ation between the substitution of alanine for proline at
codon 12 of PPAR- γ and the risk for T2DM has been
widely studied since Yen CJ, first reported this polymorph-
ism [41]. Within a unique domain of PPARγ-2 gene
that enhances ligand independent activation, a common
Pro12Ala polymorphism has been identified [5]. This poly-
morphism has been reported to be associated with obesity.
Using a family based design to control for population
stratification, it was reported that Ala allele of this poly-
morphism was associated with a decreased risk of T2DM
[36]. A meta-analysis conducted by Ludovico found that
the alanine polymorphism conferred significantly greater
protection against T2DM among Asians than Caucasians
[23], contradictory result have been reported within the
same study elsewhere where Ala12 variant was associated
with a reduced risk for the development of diabetes
[5,26,42]. Soon, it became apparent that most negativestudies had been underpowered and after combining the
data from all published studies in a meta-analysis it became
evident that Pro12Ala variant was associated with T2DM
[5,28,43]. PPAR-γ plays a critical role in glucose homeosta-
sis and serves as the molecular target for a class of insulin-
sensitizing drugs called thiazolidinediones (TZDs). TZDs is
PPARγ2 ligands and widely used for treatment of T2DM
[24], they had very minimal activity toward PPAR-α or
PPAR-β. Although PPAR- γ levels are 10–30 times higher
in fat than in muscle or liver, this receptor is expressed in
these latter tissues. Effects on insulin action in other tissues
would then occur as a consequence of alterations in signal-
ling molecules produced by fat, such as free fatty acids,
TNF-α , leptin, or others (Perspectives in Diabetes PPAR-
γ: Adipogenic Regulator and TZDs Receptor) [44]. PPAR- γ
activation controls one or more genes that regulate sys-
temic insulin sensitivity like TNF-α and leptin.
Angiotensin Converting Enzyme (ACE) gene
Genetic studies have revealed that the genes of renin
angiotensin are highly polymorphic, raising the possibility
in addition to environmental factors. The genetic make-up
of Renin Angiotensin System (RAS) affects the status of
RAS in the individuals. The emerging picture of ACE func-
tion is that it is more than just a key enzyme that catalyses
cleavage of angiotensin I to the potent vasoconstrictor pep-
tide angiotensin II [45]. ACE also hydrolyzes the inactive
angiotensin (1–9) peptide into the vasodilator metabolite
angiotensin (1–7) [46], and it is additionally thought to in-
activate the vasodilator peptides bradykinin and kallidin
[46]. Among the various SNP’s associated with RAS, one of
the examples is insertion (I)/deletion (D) polymorphism of
ACE gene, which consists of 26 exons and span 21 kb on
chromosome 17. The polymorphism exists within intron
16, consisting the presence or absence of 287 bp fragment
[47]. The II (Insertion-Insertion) genotype is reported to be
protective against development and progression of diabetic
and non-diabetic nephropathy to chronic kidney disease
[48]. Clinically, serum ACE level is useful for the evaluation
of disease activity and follow-up in T2DM [31,49-52]. All
previous studies in non-diabetic and diabetic nephropa-
thies have demonstrated that the deletion polymorphism
of ACE gene, particularly the homozygote DD, is a risk fac-
tor for an accelerated loss of kidney function [53]. Studies
of ACE gene with T2DM have shown contradictory results,
where some have shown association of ACE gene with
T2DM [7,9,31-34] while others have shown no such associ-
ation [8,35]. Indian studies, reported a strong association
of ACE gene polymorphisms with T2DM in Northern
India [29]. Vishwanathan and Bhavani established positive
association of ACE polymorphism with T2DM in south
India [54,55]; while Prasad and Ajay Kumar reported no
any relation between ACE gene and T2DM among North
Indian population [56,57].
Table 1 A comparative study of PPARγ2, ACE, MTHFR, FABP2 and FTO genes polymorphism with T2DM in various
ethnic groups
PPARG2
Ethinicity Reference OR P value 95%CI Significant (Y/N)
Japanese [22] 4.35 <0.05 Y
USA [23] 1.24 <0.05 0.99–1.57 Y
UK [24] 0.86 <0.05 0.81, 0.90 Y
Caucasians [25] 0.81 <0.05 0.72. 0.91 Y
Europeans [26] 0.81 <0.05 0.75, 0.88 Y
North Indian [27] 0.65 <0.05 0.42-0.99 Y
USA [21] 0.12 <0.05 0.03–0.52 Y
French population [28] 1.37 <0.05 Y
ACE
Ethinicity Reference OR P value 95%CI Significant (Y/N)
North Indian [29] <0.05 Y
Indian [30] 8.826 <0.05 1.012,76.96 Y
Malaysian [9] >0.05 N
Taiwanese [31] <0.05 Y
Iranian [10] 3.122 <0.05 1.12-8.64 Y
Japanese [32] 1.49 <0.05 1.01-2.21 Y
UK [7] 1.55 <0.05 0.89-2.60 Y
Turkish [33] <0.05 Y
Australian [34] 1.16 >0.05 0.94-1.43 N
Caucasians [35] >0.05 N
MTHFR
Ethinicity Reference OR P value 95%CI Significant (Y/N)
Turkish [11] 3.76 <0.05 1.28-11.00 Y
Brazilian [13] >0.05 N
Chinese [14] 4.04 <0.05 1.95-8.34 Y
North Indian [27] 0.54 <0.05 0.29-0.98 Y
FABP2
Ethinicity Reference OR P value 95%CI Significant (Y/N)
North Indian [29] >0.05 N
USA [19] <0.05 Y
FTO
Ethinicity Reference OR P value 95%CI Significant (Y/N)
North Indian [21] 1.46 <0.05 1.11–1.93 Y
South Asian Indians [36] <0.05 Y
South African [37] >0.05 N
Spanish [38] 0.97 >0.05 0.85-1.16 N
Scotland [39] <0.05 Y
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Methylenetetrahydrofolate reductase (MTHFR) has a major
impact on regulating the folic acid pathway; it catalyzes the
irreversible conversion of 5, 10‐methylenetretrahydrofolate,
which is the methyl donor (for the conversion of dUMP todTMP), into 5‐methyltetrahydrofolate. Genetic and envir-
onmental (e.g., dietary) factors play a key role in affecting
the homocysteine levels [58]. One of the most common
genetic defects of homocysteine metabolism is a mutation
in MTHFR gene. The gene encoding MTHFR is located at
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homocysteine levels and diabetic complications such as
macroangiopathy, retinopathy and nephropathy in T1DM,
whereas no such association was seen among T2DM sub-
jects [60]. Numerous polymorphisms in MTHFR gene
have been reported. Frosst et al. described a C677T substi-
tution at of MTHFR gene that converts an alanine to a
valine residue [61]. In a few studies, no association was
found between hyperhomocysteinemia, MTHFR gene
C677T polymorphism, metabolic 6 syndromes and T2DM
[62]. Nevertheless, in another study a significant correl-
ation between these polymorphisms and individuals with
normal weight and increased risks of developing metabolic
syndrome (normal weight obese syndrome) was observed
[63]. A high concentration of homocysteine was seen in
patients with diabetes mellitus [64]. The mutant homozy-
gous genotype for MTHFR C677T showed high risk of
diabetic retinopathy among the individuals with T2DM
[65]. Likewise, Ksaizek and co-workers have also found
that MTHFR C677T mutation in MTHFR gene predis-
poses T2DM patients to the development of diabetic retin-
opathy [66]. These common polymorphisms are also
associated with hyper homocysteinemia that has been re-
ported to be an increased risk factor for neural tube de-
fects, diabetes and cardiovascular diseases.
Fatty acid binding protein 2 (FABP2) gene
FABP2 plays a key role in the absorption and intracellular
transport of dietary long chain fatty acids. Since, glucose
and fatty acid metabolism are inter-related phenomenons,
FABP2 soon became an important candidate gene for
T2DM. In the search for T2DM loci in Pima Indians,
Prochazka and co-workers found linkage between insulin
resistance and a region on chromosome 4q near the FABP2
locus [67]. This finding is supported by a positive linkage
between post challenge insulin levels and FABP2 in
Mexican–Americans [68]. Molecular scanning of FABP2
identified a missense mutation (Ala54Thr) responsible for
insulin resistance [69]. Carriers of the Thr54 allele in
FABP2 have a twofold greater affinity for the absorption
for the long-chain fatty acids than those with the Ala54-
containing FABP2 [70]. Genotypic/Phenotypic studies in-
volving FABP2 have focussed on the Ala–›Thr (G–›A)
substitution in exon-2 which is responsible for increased
binding affinity, transport of long chain fatty acids and
more efficient secretion of triglycerides in cells expressing
Thr-encoding allele [69,71]. In a study of Canadian Oji-
Cree Indians, the Thr encoding allele was associated with
increased BMI, percent body fat, and plasma triglycerides
[72]. FABP2 Ala54Thr variant has been associated with an
increased fasting insulin concentration, increased rate of
lipid oxidation, reduced insulin-stimulated glucose uptake
and increased concentrations of fasting and postprandial
triglyceride-rich lipoprotein [19,70,71,73-75]. It has beensuggested that the Ala54Thr polymorphism might associ-
ate with the risk for atherosclerosis because it causes a
compositional change in LDL particles [76], an altered
postprandial lipemia [70]. Previous studies have found
contradictory associations between FABP2 genotypes and
the occurrence of T2DM, obesity or decreased insulin sen-
sitivity [17,70,71,77-79]. Contradictory to it, several studies
have reported the association between the Ala54Thr poly-
morphism of FABP2 with insulin resistance and T2DM
[17,19,69,80-82]. In contrast, studies in other Japanese
[83,84], Caucasians [85,86], and African-American [87]
cohorts have not found an association of T2DM, insulin
levels, or obesity with the Thr54 variant.
Fat Mass and Obesity associated gene (FTO)
Fat mass and obesity associated (FTO) gene was found in
a genome-wide association (GWA) study for T2DM and
showed to predispose individuals to diabetes through an
effect on Body mass Index (BMI). The FTO gene, which is
located on chromosome 16q12.2 consists nine exons and
emerged 450 million years ago [88]. FTO is primarily
expressed in the hypothalamus and encodes a 2-
oxoglutarate-dependent nucleic acid demethylase. Se-
quence analysis suggested that FTO has homology with
the AlkB family of DNA repair enzymes. Subsequent
in vitro biochemical studies revealed FTO to be a member
of the Fe (II) and 2-oxoglutarate (2OG) dependent oxy-
genase superfamily [89]. In metazoans these enzymes are
involved in diverse processes including oxygen sensing,
DNA repair, fatty acid metabolism and post-translational
modifications [90]. A number of SNPs in tight linkage dis-
equilibrium with rs9939609, and residing in the first in-
tron of the FTO gene, had been associated with obesity in
large populations of adults and children. Recently, part of
a genome-wide association study found that SNPs of the
FTO were strongly associated with obesity and T2DM
[91,92]. FTO gene encodes for a protein 2-oxoglutarate
dependent nucleic acid demethylase involved in fatty acid
metabolism, DNA repair and post- translational modifi-
cations [93]. It may also play important roles in the
management of energy homeostasis [88,94], nucleic acid
demethylation, and regulation of body fat masses by lip-
olysis [95]. The hypothalamic expression of FTO sug-
gests a potential role in the control of food intake and
whole body metabolism wherein physical activity and
food intake is unchanged but metabolic rate is increased.
The association of FTO variants with T2DM and BMI
has been independently identified in a number of white
European populations [96] but the findings are somewhat
inconsistent in Asians, which may be the result of varying
study designs, inadequate sample sizes or ethnic differences
[97-99]. A recent study in north Indian Sikhs demonstrated
a strong association of FTO variants with type 2 diabetes,
which did not seem to be mediated through BMI [21]. This
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variants with BMI and T2DM might be different in
Asian populations. FTO gene confers risk for T2DM in
Europeans, with each A allele increasing BMI by ap-
proximately 0.4 kg/m2 [100]. However, results have been
variable for replication in other ethnic populations such as
Hispanics [101], Asians, Oceanics [102] and Blacks [103].
Conclusion
Multiple genes are involved in pathogenesis of T2DM,
each contributing a small amount to the overall risk
making T2DM, a truly complex disorder. Our under-
standing of genetics of diseases gives a better prospective
of biochemical and molecular mechanism of disease on
the whole. The data could help to identify at-risk pa-
tients in early stages and may provide opportunities for
early prevention. Our better understanding of such phe-
nomena will throw new light on how common variants
can alter disease susceptibility and it is necessary to
understand the physiologic importance of the genetic as-
sociations those are uncovered. The utility of genetic ap-
proaches will depend on a holistic understanding of the
interactions among the genes and also between genes
and the environment. Combining these genetic varia-
tions with new developments in the fields of bioinfor-
matics, genomics, and proteomics will lead to a greater
understanding of the pathogenesis of T2DM and may
present new information on diagnostics, treatment and
eventual prevention of the disease. Additionally, inclu-
sion of genetic studies in design and analysis of drug tri-
als could lead to development of genetic biomarkers that
predict treatment response. Prediction can be made on
the basis of biomarkers in connection to the course of
disease; treatment-response and possibilities of side-
effects will be vastly appreciated. As a result of wide
range of investigations over the last few years, a few bio-
markers have been introduced into clinical practices.
This requires a personalized medicine approach. This
genetic information may also form the basis for develop-
ment of new drug therapies such as individually specific
or targeted pharmacotherapy. Thus, an understanding of
common variants and of the genetic/non-genetic factors
with which they interact can improve public health by
focussing on genetic individuality in the diagnosis and
treatment of disease.
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